These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 23220353)
21. Clinical characteristics of itch in cutaneous lupus erythematosus: A prospective, multicenter, multinational, cross-sectional study. Samotij D; Szczęch J; Antiga E; Bonciani D; Caproni M; Chasset F; Dańczak-Pazdrowska A; Furukawa F; Hasegawa M; Hashizume H; Ikeda T; Islam A; Kim HJ; Lesiak A; Misery L; Mowla MR; Polańska A; Szepietowski JC; Tsuruta D; Verdelli A; Werth VP; Reich A Lupus; 2021 Aug; 30(9):1385-1393. PubMed ID: 34000879 [TBL] [Abstract][Full Text] [Related]
22. Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus. Stannard JN; Kahlenberg JM Curr Opin Rheumatol; 2016 Sep; 28(5):453-9. PubMed ID: 27270345 [TBL] [Abstract][Full Text] [Related]
23. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers. Carter LM; Wigston Z; Laws P; Vital EM Br J Dermatol; 2023 Jul; 189(2):210-218. PubMed ID: 36944572 [TBL] [Abstract][Full Text] [Related]
24. Robust measurement of clinical improvement in patients with cutaneous lupus erythematosus. Nanes BA; Zhu JL; Chong BF Lupus Sci Med; 2020; 7(1):e000364. PubMed ID: 32095249 [TBL] [Abstract][Full Text] [Related]
25. Cutaneous lupus erythematosus: factors related to cutaneous activity and damage in a cohort of 260 patients from A Coruña, Spain. Arévalo-Bermúdez MDP; Paradela S; Balboa-Barreiro V; Fonseca E Lupus; 2020 Aug; 29(9):1021-1030. PubMed ID: 32539659 [TBL] [Abstract][Full Text] [Related]
26. The use of SLICC and ACR criteria to correctly label patients with cutaneous lupus and systemic lupus erythematosus. Flynn A; Gilhooley E; O'Shea F; Wynne B Clin Rheumatol; 2018 Mar; 37(3):817-818. PubMed ID: 29392510 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Wenzel J; Brähler S; Bauer R; Bieber T; Tüting T Br J Dermatol; 2005 Jul; 153(1):157-62. PubMed ID: 16029342 [TBL] [Abstract][Full Text] [Related]
28. Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review. Chasset F; Francès C Drugs; 2019 Jul; 79(11):1199-1215. PubMed ID: 31228033 [TBL] [Abstract][Full Text] [Related]
29. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. Tzellos TG; Kouvelas D Eur J Clin Pharmacol; 2008 Apr; 64(4):337-41. PubMed ID: 18157526 [TBL] [Abstract][Full Text] [Related]
30. A review of the evidence and cost of therapies for cutaneous lupus erythematosus. Rosen JD; Paul S; Maderal A Lupus; 2019 Jun; 28(7):799-805. PubMed ID: 31042129 [TBL] [Abstract][Full Text] [Related]
31. Management of cutaneous manifestations of lupus erythematosus: A systematic review. Fairley JL; Oon S; Saracino AM; Nikpour M Semin Arthritis Rheum; 2020 Feb; 50(1):95-127. PubMed ID: 31526594 [TBL] [Abstract][Full Text] [Related]
32. Photoprotection awareness and practices among patients with systemic lupus erythematosus and its association with disease activity and severity. Abdul Kadir WD; Jamil A; Shaharir SS; Md Nor N; Abdul Gafor AH Lupus; 2018 Jul; 27(8):1287-1295. PubMed ID: 29665756 [TBL] [Abstract][Full Text] [Related]
33. Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. Wieczorek IT; Propert KJ; Okawa J; Werth VP JAMA Dermatol; 2014 Mar; 150(3):291-6. PubMed ID: 24477339 [TBL] [Abstract][Full Text] [Related]
35. ARA and EADV criteria for classification of systemic lupus erythematosus in patients with cutaneous lupus erythematosus. Parodi A; Rebora A Dermatology; 1997; 194(3):217-20. PubMed ID: 9187836 [TBL] [Abstract][Full Text] [Related]
36. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998 [TBL] [Abstract][Full Text] [Related]
37. Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. Lu Q; Long H; Chow S; Hidayat S; Danarti R; Listiawan Y; Deng D; Guo Q; Fang H; Tao J; Zhao M; Xiang L; Che N; Li F; Zhao H; Lau CS; Ip FC; Ho KM; Paliza AC; Vicheth C; Godse K; Cho S; Seow CS; Miyachi Y; Khang TH; Ungpakorn R; Galadari H; Shah R; Yang K; Zhou Y; Selmi C; Sawalha AH; Zhang X; Chen Y; Lin CS J Autoimmun; 2021 Sep; 123():102707. PubMed ID: 34364171 [TBL] [Abstract][Full Text] [Related]
38. Management of "refractory" skin disease in patients with lupus erythematosus. Callen JP Best Pract Res Clin Rheumatol; 2005 Oct; 19(5):767-84. PubMed ID: 16150402 [TBL] [Abstract][Full Text] [Related]
39. Diagnostic approach and treatment of cutaneous lupus erythematosus. Sticherling M; Bonsmann G; Kuhn A J Dtsch Dermatol Ges; 2008 Jan; 6(1):48-59. PubMed ID: 18190433 [TBL] [Abstract][Full Text] [Related]